Annual Report 2023
Cancer Screening Center
Nozomu Kobayashi, Yasuo Kakugawa, Masau Sekiguchi, Keiko Nakamura, Izumi Hisada, Eriko Tsuruki, Takaaki Tsuchida, Masahiko Kusumoto, Nachiko Uchiyama, Mari Kikuchi, Kimiteru Ito, Mototaka Miyake, Miwako Takahashi, Kota Yokoyama, Mitsuya Ishikawa, Masaya Uno, Yasuhito Tanase, Mayumi Kato, Kenichi Nakamura, Hiroshi Katayama, (Visiting Researcher) Takahisa Matsuda, Shuji Yamamoto, Hidetsugu Yamagishi, (Special Research Assistant) Mika Mori
Introduction
In the Cancer Screening Center (former name: Research Center for Cancer Prevention and Screening; RCCPS), we have provided broad opportunistic cancer screening using newly developed modalities since 2004. Most staff doctors hold two positions concurrently in both the Cancer Screening Center and their specialized department. Our department is in charge of multiphasic cancer screening using several imaging modalities to develop new cancer screening systems and to assess new screening tests.
The Team and What We Do
1. Cancer screening courses: The basic plan for males consists of screening for cancer of the lungs, esophagus, stomach, colorectum, liver, gall bladder, pancreas, kidneys, and prostate. The basic plan for females consists of screening for cancer of the breast, uterus, and ovaries, in addition to the plan for males, excluding the prostate. In addition, PET (positron emission tomography) is provided as an option. In addition to multiphasic programs, an independent cancer screening program has been prepared for cancers of the lungs and female genitalia, including cancer of the uterus, ovaries, breast, and gastrointestinal tract. Blood samples are also obtained for biochemistry and tumor markers such as CA19-9, CEA, CA125, and PSA, as well as for genetic analysis.
2. Cancer screening methods: On the first day, the multiphasic cancer screening programs (comprehensive cancer screening program) perform CT for lung cancer, abdominal US for cancer of the liver, gall bladder, pancreas, and kidneys, gynecological examinations with pap-smear and HPV test for uterine cancer, and MMG/tomosynthesis and US for breast cancer. On the following day, gastroscopy for cancer of the esophagus and stomach, and total colonoscopy for cancer of the colon and rectum are conducted. Moreover, from the beginning of December 2010, CT-colonography (CTC) has been provided as an option for cancer screening. FDG-PET/CT is offered on the first day as an option, if the participants wish to undergo the examination. Furthermore, FDG-PET/MRI has been provided as an optional examination since 2018.
3. Number of cancer screening participants: The number of cancer screening participants between April 2023 and March 2024 is shown in this report (Table 1). Due to the influence of COVID-19, the number of participants decreased remarkably. A total of 2,769 people underwent cancer screening at the Cancer Screening Center during this period. Most of the participants (2,554) chose the comprehensive cancer screening course. Regarding the cancer detection rate data in each modality, we will report them in the near future.
Research Activities
1. Amino-index (AICS) cancer screening accuracy evaluation study
Since the start of the research in July 2012, we have received plasma samples from 8,111 screening examinees and are proceeding with comprehensive amino acid analysis. This year, we confirmed the results of AICS in patients with colorectal cancer, using data from 6,533 individuals. Among thirty-eight patients with colorectal cancer, only three were classified as rank C, the highest risk group. The sensitivity and specificity of AICS for colorectal cancer were 8% and 94%, respectively.
2. Study using colorectal cancer screening data from colonoscopy (CS)
The AP-Colon SL study is a prospective study of colorectal serrated lesions in patients undergoing colorectal cancer screening at multicenter sites in the Asia-Pacific region, aiming to determine the true prevalence of serrated lesions and to identify the risk factors for colorectal serrated lesions. For the total colonoscopy, the protocol stipulates that all patients will undergo right-sided colonoscopy with dye endoscopy using indigo carmine to detect serrated colorectal lesions more reliably and to determine their true prevalence. The planned enrollment of 1,000 patients was completed in November, and its analysis is ongoing.
Clinical Trials
We are conducting ongoing research based on the study protocol titled “Evaluation of effectiveness of cancer screening modality at the National Cancer Center”. The target modalities are as follows: 1) upper gastrointestinal endoscopy, 2) lower gastrointestinal endoscopy, 3) CT colonography, 4) chest computed tomography (CT), 5) sputum cytology, 6) mammography, 7) breast ultrasonography, 8) FDG-positron emission tomography (PET), 9) abdominal ultrasonography, and 10) serum tumor markers.
Future Prospects
Based on cancer screening data such as examination results, medical institution findings, follow-up findings, and the questionnaire survey concerning lifestyles for 10 years, we assessed them with the support of the National Cancer Center Research and Development Fund.
List of papers published in 2023
Journal
1. Sano Y, Hotta K, Matsuda T, Murakami Y, Fujii T, Kudo SE, Oda Y, Ishikawa H, Saito Y, Kobayashi N, Sekiguchi M, Ikematsu H, Katagiri A, Konishi K, Takeuchi Y, Iishi H, Igarashi M, Kobayashi K, Sada M, Osera S, Shinohara T, Yamaguchi Y, Hasuda K, Morishima T, Miyashiro I, Shimoda T, Taniguchi H, Fujimori T, Ajioka Y, Yoshida S. Endoscopic Removal of Premalignant Lesions Reduces Long-Term Colorectal Cancer Risk: Results From the Japan Polyp Study. Clinical gastroenterology and hepatology, 22:542-551.e3, 2024
2. Kawamura T, Sekiguchi M, Takamaru H, Mizuguchi Y, Horiguchi G, Toyoizumi H, Kato M, Kobayashi K, Sada M, Oda Y, Yokoyama A, Utsumi T, Tsuji Y, Ohki D, Takeuchi Y, Shichijo S, Ikematsu H, Matsuda K, Teramukai S, Kobayashi N, Matsuda T, Saito Y, Tanaka K. Endoscopist-related factors affecting adenoma detection during colonoscopy: Data from the J-SCOUT study. Digestive endoscopy, 36:51-58, 2024
3. Sekiguchi M, Matsuda T, Saito Y. Treatment strategy and post-treatment management of colorectal neuroendocrine tumor. DEN open, 4:e254, 2024
4. Saito Y, Sakamoto T, Dekker E, Pioche M, Probst A, Ponchon T, Messmann H, Dinis-Ribeiro M, Matsuda T, Ikematsu H, Saito S, Wada Y, Oka S, Sano Y, Fujishiro M, Murakami Y, Ishikawa H, Inoue H, Tanaka S, Tajiri H. First report from the International Evaluation of Endoscopic classification Japan NBI Expert Team: International multicenter web trial. Digestive endoscopy, 36:591-599, 2024
5. Takuma K, Kimura Y, Okano N, Nakagawa H, Watanabe K, Yamada Y, Iwasaki S, Ito K, Igarashi Y, Matsuda T. Two-devices-in-one-channel method for fractured pancreatic duct stent retrieval in a case of severe chronic pancreatitis. Journal of hepato-biliary-pancreatic sciences, 31:e1-e2, 2024
6. Ito Y, Hamaguchi T, Takashima A, Mizusawa J, Shimada Y, Shiozawa M, Mizoguchi N, Kodaira T, Komori K, Ohue M, Konishi K, Teraishi F, Kinouchi M, Murata K, Fujita F, Watanabe M, Iinuma G, Ishida F, Saida Y, Matsuda T, Katayama H, Fukuda H, Kanemitsu Y. Definitive S-1/mitomycin-C chemoradiotherapy for stage II/III anal canal squamous cell carcinoma: a phase I/II dose-finding and single-arm confirmatory study (JCOG0903). International journal of clinical oncology, 28:1063-1072, 2023
7. Suzuki H, Nonaka S, Maetani I, Matsuda T, Abe S, Yoshinaga S, Oda I, Yamagata Y, Yoshikawa T, Saito Y. Clinical and endoscopic features of metachronous gastric cancer with possible lymph node metastasis after endoscopic submucosal dissection and Helicobacter pylori eradication. Gastric cancer, 26:743-754, 2023
8. Kajiwara Y, Oka S, Tanaka S, Nakamura T, Saito S, Fukunaga Y, Takamatsu M, Kawachi H, Hotta K, Ikematsu H, Kojima M, Saito Y, Yamada M, Kanemitsu Y, Sekine S, Nagata S, Yamada K, Kobayashi N, Ishihara S, Saitoh Y, Matsuda K, Togashi K, Komori K, Ishiguro M, Kuwai T, Okuyama T, Ohuchi A, Ohnuma S, Sakamoto K, Sugai T, Katsumata K, Matsushita HO, Yamano HO, Eda H, Uraoka T, Akimoto N, Kobayashi H, Ajioka Y, Sugihara K, Ueno H. Nomogram as a novel predictive tool for lymph node metastasis in T1 colorectal cancer treated with endoscopic resection: a nationwide, multicenter study. Gastrointestinal endoscopy, 97:1119-1128.e5, 2023
9. Kawamura T, Sekiguchi M, Takamaru H, Mizuguchi Y, Horiguchi G, Kato M, Kobayashi K, Sada M, Oda Y, Yokoyama A, Utsumi T, Tsuji Y, Ohki D, Takeuchi Y, Shichijo S, Ikematsu H, Matsuda K, Teramukai S, Kobayashi N, Matsuda T, Saito Y, Tanaka K. "Endoscopic" adenoma detection rate as a quality indicator of colonoscopy: First report from the J-SCOUT study. Digestive endoscopy, 35:615-624, 2023
10. Hihara D, Takamaru H, Sekiguchi M, Yamada M, Sakamoto T, Matsuda T, Saito Y. Factors associated with increased duration of endoscopic submucosal dissection for rectal tumors: a 22-year retrospective analysis. Gastrointestinal endoscopy, 98:420-427.e1, 2023
11. Sekiguchi M, Igarashi A, Toyoshima N, Takamaru H, Yamada M, Esaki M, Kobayashi N, Saito Y. Cost-effectiveness analysis of computer-aided detection systems for colonoscopy in Japan. Digestive endoscopy, 35:891-899, 2023
12. Ishikawa H, Yamada M, Sato Y, Tanaka S, Akiko C, Tajika M, Doyama H, Takayama T, Ohda Y, Horimatsu T, Sano Y, Tanakaya K, Ikematsu H, Saida Y, Ishida H, Takeuchi Y, Kashida H, Kiriyama S, Hori S, Lee K, Tashiro J, Kobayashi N, Nakajima T, Suzuki S, Mutoh M. Intensive endoscopic resection for downstaging of polyp burden in patients with familial adenomatous polyposis (J-FAPP Study III): a multicenter prospective interventional study. Endoscopy, 55:344-352, 2023
13. Takamaru H, Saito Y, Toyoshima N, Yamada M, Sakamoto T, Matsuda T. Polyglycolic acid sheet with clipping for closing delayed perforation after colonic endoscopic submucosal dissection. Endoscopy, 55:E211-E213, 2023
14. Ito K, Okano N, Takuma K, Iwasaki S, Watanabe K, Kimura Y, Yamada Y, Yoshimoto K, Hara S, Kishimoto Y, Matsuda T, Igarashi Y. Are Newer Extracorporeal Shock Wave Lithotripsy Models Truly Improving Pancreatolithiasis Lithotripsy Performance? A Japanese Single-Center Study Using Endoscopic Adjunctive Treatment. Gut and liver, 17:647-658, 2023
15. Hayashi Y, Kaneko R, Ogino H, Uekusa T, Kitajima M, Ikehara T, Nagai H, Matsuda T. A case of multiple hepatocellular carcinoma experiencing complete responses to sorafenib and atezolizumab-bevacizumab and developing severe, refractory venous congestive cutaneous ulcers on either regimen. Clinical journal of gastroenterology, 16:229-236, 2023
16. Ogino Y, Wakui N, Nagai H, Matsuda T. Comparison of strain elastography and shear wave elastography in diagnosis of fibrosis in nonalcoholic fatty liver disease. Journal of medical ultrasonics (2001), 50:187-195, 2023
17. Abe SK, Ihira H, Minami T, Imatoh T, Inoue Y, Tsutsumimoto K, Kobayashi N, Kashima R, Konishi M, Doi T, Teramoto M, Kabe I, Lee S, Watanabe M, Dohi S, Sakai Y, Nishita Y, Morisaki N, Tachimori H, Kokubo Y, Yamaji T, Shimada H, Mizoue T, Sawada N, Tsugane S, Iwasaki M, Inoue M. Prevalence of family history of cancer in the NC-CCAPH consortium of Japan. Scientific reports, 13:3128, 2023
18. Toba T, Ikegami R, Nogami A, Watanabe N, Fujii K, Ogawa Y, Hojo A, Fujimoto A, Matsuda T. Multiple ulcerative colitis-associated aseptic abscesses successfully treated with infliximab: a case report. Clinical journal of gastroenterology, 16:537-542, 2023
19. Yoshida Y, Maetani I, Shigoka H, Matsuda T. Preprocedural control of nutritional status score and prediction of early death after percutaneous endoscopic gastrostomy. JGH open, 7:504-508, 2023
20. Kikuchi Y, Yamaguchi K, Shimizu R, Matsumoto Y, Kurose Y, Okano N, Otsuka Y, Shibuya K, Matsuda T, Shimada H. Intrahepatic cholangiocarcinoma with FGFR2 fusion gene positive that responded to pemigatinib and caused hypophosphatemia. International cancer conference journal, 12:285-290, 2023
21. Saito E, Mutoh M, Ishikawa H, Kamo K, Fukui K, Hori M, Ito Y, Chen Y, Sigel B, Sekiguchi M, Hemmi O, Katanoda K. Cost-effectiveness of preventive aspirin use and intensive downstaging polypectomy in patients with familial adenomatous polyposis: A microsimulation modeling study. Cancer medicine, 12:19137-19148, 2023
22. Kobayashi K, Nagai H, Matsui T, Matsuda T, Higai K. Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma. Anticancer research, 43:4601-4609, 2023
23. Ono M, Fujimoto A, Yamaguchi K, Toba T, Matsuda T. A new treatment method for patients with cancer that cannot be resected en bloc by endoscopic submucosal dissection: the monorail method with clip-line traction. Endoscopy, 55:E1118-E1119, 2023